HR Execs on the Move

Onconano Medicine

www.onconanomed.com

 
OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Tian Zhao
Vice President, Research and Development Profile
Ravi Srinivasan
Founder President and Chief Executive Officer Profile

Similar Companies

Conagen

Conagen is a #syntheticbiology leader, supporting our global partners through #enzymatic and #microbial platforms and #biomanufacturing capabilities.

Azitra

Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease.

Southwest Foundation For Biomedical Research

Southwest Foundation For Biomedical Research is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Avista Pharma

Avista Pharma Solutions is a contract development and manufacturing organization (CDMO) formed through the recent, strategic carve-outs of the CMC business of Array BioPharma, Inc. and contract services business of Scynexis, Inc. These two operations, along with the microbiology and analytical testing capabilities of the parent company Accuratus, create a combined business encompassing over 170,000 square feet of laboratory and manufacturing space which is capable of providing pharmaceutical clients with a broad suite of scientifically-differentiated services. These services are provided from a team with demonstrated expertise in process chemistry, analytical chemistry, manufacturing of novel drugs and specialized animal health services.

Bio-Techne

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions including T-Cell activation technologies. Bio-Techne`s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers, as well as clinical research laboratories, and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for OEM and clinical customers. Bio-Techne`s genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand, as well as a portfolio of clinical molecular diagnostic oncology assays including the ExoDx®Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne`s Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $714 million in net sales in fiscal 2019 and has over 2,200 employees worldwide.